The sequence of events is interesting and raises nothing
The sequence of events is interesting and raises nothing but questions for me.
1. merge with Protegene after Dr Pestel contacts Cytodyn with Dr Pestell stating that cytodyn does not realize what they have. Dr Pestell goes all in with giving up IP, patents and basically his life's work in exchange for shares and a board seat.
2. Nader makes a long list of accomplishments we can look forward to this year and a big chunk of them are Dr Pestell's resonsibility. Most of them have not been accomplished yet and Nader in a recent interview takes responsibility for the TNBC delay and states a plan to fix the situation will be presented soon.
3. The TO is extended 1 week to include a CC prior to it's closing and today's announcement that Dr Pestell is fired.
My guess is that DR Pestell would not just give away his life's work for shares in a company and just blow off the cancer trials. I also feel that Nader is under a huge amount of pressure to deliver on the accomplishments yet to happen and he does not seem to be someone who lacks drive to resolve problems that impede progress in his life's work. There must have been a power struggle between them or between Dr Pestell and the rest of the BOD. It could be the Prognostic test licensing was sold as a done deal when the company realized it was far from it. It could be Dr Pestell was leveraging the cancer trials to get Nader out of the picture.
The things that don't make sense however is that I would think that if there was some deal brewing with BP, Dr Pestell would likely be concerned of losing control of the cancer trials. Nader has been the one talking the "go it alone" plan for some time so I felt he was also not eager to sell out too soon either. If the Cancer trials were going too slow, Nader could have replaced Dr Pestell and not fired him, What prompted such a dramatic move? If Dr Pestell was in some plan to take control of the company, He might have had to move faster than he thought given the status of deals and the speed of the cancer IND approval. It could be his plan got foiled for now but I doubt this is the last of it.
Unfortunately, I doubt we will get enough details. The extension of the TO might be just so the warrant holders considering converting have all the facts prior to the TO closing. Could be a good thing, could be a bad thing.
1
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Diving Headfirst into Holiday Tech Splurging The holiday hustle is upon us, folks, and Epson's stepping up with early Black Friday deals that'll have tech heads scrambling. They’re cutting prices up to $250 on their swanky home lineup—projectors, printers, scanners, you name it. This ain't just about making someone else smile, though; it's about the sweet spot where...
Continue Reading
Oxford Computer Group Strikes Again Another day, another nod from the big boys at Microsoft, eh? Oxford Computer Group, now part of MajorKey Technologies, hasn't just found themselves in the mix—they're standing tall as a finalist for not one but two significant categories in the 2026 Microsoft Partner of the Year Awards: Secure Access and Defense and Intelligence. You...
Continue Reading
Breathing Life into an Ancient Waterway You'd think the Yangtze River story's as old as the hills—well, you're not wrong. But today, there's a fresh wind blowing down its waters. On November 10, scholars, cultural buffs, and a mixed bag of experts moseyed into Nanjing. They weren't just there to nibble dumplings and wax poetic; they were fixing to shed new light on the...
Continue Reading
The Smart Shopper's Guide to Black Friday Tech Black Friday ain't just a race for the cheapest jeans or a half-price TV anymore—now we're talking about smart tech that matters, like Lovense's offerings. Imagine shelling out for something that'll last and deliver genuine satisfaction instead of another closet filler. Yeah, I'm looking at you, cheap gadgets that croak in...
Continue Reading
A Remarkable Milestone in Healthcare Leadership It's not every day someone hangs up their boots after 46 years of relentlessly steering the ship, especially in the tumultuous seas of healthcare. Come June 1, 2027, Lee Ann Stember plans to do just that as she retires as President & CEO of the National Council for Prescription Drug Programs (NCPDP). Her tenure is marked by...
Continue Reading
Revolutionizing Cancer Treatment: Immunofoco's Approach In the battle against B-cell malignancies, the old ways of doing things sometimes just don’t cut it, folks. Enter Immunofoco. At the recent Society for Immunotherapy of Cancer (SITC) 2026 meeting, they laid some ambitious cards on the table with their in vivo T-cell engager (TCE) delivery strategy. Engineering...
Continue Reading
Unifying the Landscape: Group 1's Bold Move with Lexus Gwinnett Another piece of the puzzle drops into place as Group 1 Automotive continues its aggressive campaign to unify its dealership network. The latest acquisition sees the Hennessy Lexus of Gwinnett rebranded as Lexus Gwinnett, adding another notch to their belt in the bustling Atlanta-market corridor. Group 1's...
Continue Reading
AI and Dental Credentialing: A Game Changer? Is it just me, or is this push to AI-driven workflows becoming the latest buzz in every industry? Now, Capline Dental Services out of Houston says they've cracked the code on dental credentialing and, boy, is it something. By introducing AI into the mix, they've reportedly slashed credentialing time by 60%. You know what that...
Continue Reading
Revenue's down by a hair, but it's not as bleak as it seems. CAE Inc. (NASDAQ:CAE) just put its cards on the table for Q2 of fiscal 2027, and there's a mixed bag for us investors to chew over. Revenue dipped 2.6% year-over-year to $1,204.7 million. But hey, their adjusted EPS has climbed up to $0.33, a step up from $0.28 last year, which is a good sign of something right...
Continue Reading
A Social Revolution in King of Prussia Look, this ain't your typical bar review. We're talking about the Uncanny Comics and Kava Bar at King of Prussia Mall—where comic books, collectible treasures, and good company collide with a South Pacific vibe. Kava: Beyond Just Another Drink First off, if you're scratching your head about kava, don't fret. It's a beverage made...
Continue Reading
Top 5 Most Recently Viewed Articles
SKG Unveils New Deep Tissue Massagers for Holiday Season As the holiday shopping season approaches, SKG, a premier brand in smart massagers, is introducing its newest range of wearable deep tissue massagers. These innovative products are designed to provide effective relief from muscle tension and discomfort, making them perfect gifts for friends and family this year....
Continue Reading
Understanding Recent Analyst Upgrades Wall Street analysts have recently revised their outlook on several prominent stocks, reflecting increased confidence in their performance. This roundup highlights the key upgrades and what they mean for investors looking to make informed decisions. Microsoft Corporation (NASDAQ: MSFT) Oppenheimer analyst Brian Schwartz has raised his...
Continue Reading
BioRestorative Therapies at the 2025 Maxim Growth Summit BioRestorative Therapies, Inc. (NASDAQ:BRTX), an innovator in regenerative medicine, is set to participate in the upcoming 2025 Maxim Growth Summit. This significant event will be hosted from October 22nd to 23rd at The Hard Rock Hotel NYC, where key industry leaders gather to discuss advancements and trends in...
Continue Reading
Lantheus Holdings Faces Class Action Lawsuit Recently, it has come to light that the law firm Gainey McKenna & Egleston has filed a class action lawsuit against Lantheus Holdings, Inc. (NASDAQ: LNTH). This lawsuit was initiated in the United States District Court for the Southern District of New York and is aimed at protecting the interests of investors who acquired...
Continue Reading
Understanding Gen Z's Trust in Online Brands Recent insights reveal that trust plays a crucial role in the online behavior of Gen Z consumers, more than in any other generation. In a global survey conducted by Queue-it, it was shown that this demographic shows strong loyalty and willingness to spend on brands they trust. Survey Highlights: Trust Drives Consumer Loyalty...
Continue Reading